Skip to main content
    M

    Mural Oncology plc (MURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.04
    +0.00 (+0.00%)

    Market Cap: $35.38M

    Last updated: Nov 06, 2026 at 4:00 PM ET

    Mural Oncology plc (MURA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2025. Financial statements from company filings, amounts in US dollars.

    Mural Oncology reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$128.51M, operating cash flow was -$128.54M and free cash flow was -$128.64M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$3.71M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $138.26M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2021 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021
    Cost of revenue$0$0$0$1.47M
    Gross profit$0$0$0-$1.47M
    Research and development$110.67M$165.53M$167.19M$159.82M
    Operating income-$138.26M-$196.24M-$184.92M-$175.37M
    Net income-$128.51M-$207.45M-$189.81M-$175.43M
    EBITDAN/A-$193.67M-$183.38M-$173.89M
    Fiscal years ended Dec 2021 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$0$3.49M$0$0$0$2.62M$0$0$0$0
    Gross profit$0$0$0-$868.00K$0$0$0$2.00M$0$0$0-$497.00K
    Operating income-$3.97M-$48.84M-$34.38M-$35.85M-$34.10M-$34.28M-$34.03M-$58.51M-$46.31M-$47.26M-$44.16M-$57.59M
    Net income-$3.71M-$47.98M-$33.14M-$34.27M-$31.76M-$31.56M-$30.92M-$59.54M-$51.28M-$50.16M-$46.47M-$58.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $5.56M by $109.90M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021
    Total assets$169.39M$301.75M$33.75M$35.11M
    Current assets$152.92M$277.34M$4.82M$4.24M
    Cash and equivalents$115.46M$270.85M$0-$25.31M
    Total liabilities$28.89M$37.93M$55.41M$52.99M
    Short-term debt$5.56M$6.10M$5.84M$5.92M
    Shareholder equity$140.50M$263.82M-$21.66M-$17.88M
    Fiscal years ended Dec 2021 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$65.76M$87.56M$132.08M$169.39M$203.27M$234.93M$263.50M$301.75M$30.20M$300.98MN/A$33.75M
    Total liabilities$10.57M$28.77M$24.19M$28.89M$29.13M$30.36M$28.58M$37.93M$37.09M$16.46MN/A$55.41M
    Cash and equivalents$58.87M$77.09M$106.68M$115.46M$111.02M$121.59M$107.26M$270.85M-$16.48M$273.34MN/A-$19.39M
    Shareholder equity$55.19M$58.78M$107.89M$140.50M$174.14M$204.57M$234.93M$263.82M-$6.89M$284.52MN/A-$21.66M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$128.54M-$194.25M-$168.59M-$156.67M
    Capital expenditures$92.00K$3.45M$5.51M$4.38M
    Free cash flow-$128.64M-$197.70M-$174.10M-$161.05M
    Investing cash flow-$25.33M-$3.45M-$5.51M-$4.38M
    Financing cash flow$196.00K$468.81M$174.10M$161.05M
    Fiscal years ended Dec 2021 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$18.48M-$31.36M-$36.80M-$31.77M-$30.08M-$29.36M-$37.34M-$42.73M-$50.47M-$45.32M-$55.74M-$37.89M
    Capital expenditures$0$5.00K$10.00K$23.00K$14.00K$0$55.00K$1.18M$1.17M$710.00K$398.00K$143.00K
    Free cash flow-$18.48M-$31.37M-$36.81M-$31.79M-$30.09M-$29.36M-$37.39M-$43.90M-$51.64M-$46.03M-$56.13M-$38.03M
    Last 12 quarters

    Frequently Asked Questions About MURA

    What is Mural Oncology's annual revenue?

    Mural Oncology reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is Mural Oncology profitable?

    No. Mural Oncology reported net income of -$128.51M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does MURA generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$128.54M minus capital expenditures of $92.00K produced free cash flow of -$128.64M.

    How much debt does Mural Oncology have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $5.56M and cash and equivalents of $115.46M.